TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01395329

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
Description: The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to Acetylcholine
Description: The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to Acetylcholine
Description: The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FBF response to Acetylcholine
Description: The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to Sodium Nitroprusside
Description: The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to Sodium Nitroprusside
Description: The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FBF response to Sodium Nitroprusside
Description: The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to BQ-123+BQ-788+ACh
Description: The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to BQ-123+BQ-788+ACh
Description: The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FBF response to BQ-123+BQ-788+ACh
Description: The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
Study: NCT04152512

Intervention type: BEHAVIORAL
Intervention: Questionnaire administration
Description: Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
Study: NCT04702490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET409 Active
Description: MET409 Active (50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET409 Active
Description: MET409 Active (50mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MET409 Placebo
Description: MET409 Placebo (50mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MET409 Placebo
Description: MET409 Placebo (50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin (10mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin (10mg)
Study: NCT05820971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-short plus usual practice
Description: Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~* Outcomes (6a)~* Sample size (7a)~* Sequence generation (8a)~* Allocation concealment (9)~* Blinding (11a)~* Outcomes and estimation (17a/b)~* Harms (19)~* Registration (23)~* Protocol (24)~* Funding (25)
Study: NCT01001442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT062
Description: intravenous administration
Study: NCT04210752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1 (EG-HZ-001)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2 (EG-HZ-002)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3 (EG-HZ-003)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection
Study: NCT03319602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double trunk mask add above a nasal canulae
Description: oxygenation only with nostril prongs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double trunk mask add above a nasal canulae
Description: oxygenation only with nostril prongs
Study: NCT04472962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-exercise meal
Description: Mixed meal with low-carbohydrate-high-protein content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-exercise meal
Description: Mixed meal with high-carbohydrate-low-protein content
Study: NCT01512758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets
Study: NCT01934842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP20-C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAFE-T-FILL
Study: NCT03237910

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMSA
Description: A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Defibrillation
Description: delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillation
Description: delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR
Description: chest compressions and ventilations at a rate of 30:2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPR
Description: chest compressions and ventilations at a rate of 30:2
Study: NCT01347359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one peer support
Description: The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program).
Study: NCT01979250

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DSAEK surgery
Description: Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
Study: NCT04898452

Intervention type: OTHER
Intervention: A new model of interaction across health services with use of welfare technology and telemedicine
Description: Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.

Intervention type: OTHER
Intervention: A new model of interaction across health services with use of welfare technology and telemedicine
Description: Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.

Intervention type: OTHER
Intervention: A new model of interaction across health services with use of welfare technology and telemedicine
Description: Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
Study: NCT06128486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens
Description: Vision Correction
Study: NCT00956072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: Patients receive imatinib mesylate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery
Study: NCT03091179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: active nasal oxygen delivery system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: a plastic tube for mechanical ventilation
Study: NCT03723356

Intervention type: DIAGNOSTIC_TEST
Intervention: Siemens Biograph mMR (molecular MR)
Description: 5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,

Intervention type: DIAGNOSTIC_TEST
Intervention: Siemens Biograph mMR (molecular MR)
Description: 5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion Spectrum Imaging (DSI)
Description: DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion Spectrum Imaging (DSI)
Description: DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
Study: NCT04210752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 4 (EG-HZ-004)
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 5
Description: Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection
Study: NCT04842539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Nutritional supplementation and other supportive measures as per standard guidelines
Study: NCT02598180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VergenixTM Flowable Gel
Description: The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
Study: NCT01782014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: colonoscopy using different methods of insufflation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: colonoscopy using different methods of insufflation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy using different methods of insufflation
Study: NCT04264325

Intervention type: OTHER
Intervention: diaphragmatic ultrasound measure
Description: patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis
Study: NCT04791917

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Concentric Biceps Flexion
Description: Muscle shortening biceps exercise
Study: NCT01610492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: 10mg/kg administered intravenously
Study: NCT03315078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Administered by IV infusion at a dose of 60 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Administered by IV infusion at a dose of approximately 3 mg/kg per day
Study: NCT04071834

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Detection of blood orphanin and norepinephrine in patients

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Detection of blood orphanin and norepinephrine in patients
Study: NCT04292444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
Study: NCT01964079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Study: NCT03138408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-004
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-004
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous
Study: NCT02784145

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resistant starch

Intervention type: OTHER
Group type: OTHER
Intervention: Recommendation with regard to nutrition
Description: Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
Study: NCT04534699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: KBP-5074 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: KBP-5074 tablet
Study: NCT00139360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Anti angiogenesis treatment
Study: NCT03340090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Hemopatch-PEG-coated collagen patch
Description: Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
Study: NCT03314909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Description: Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
Study: NCT03573375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
Study: NCT01027455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device
Description: Humidified warm carbon dioxide gas insufflation during laparosopic procedure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic Appendicectomy
Description: Dry and Cold carbon dioxide gas insufflation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendicectomy
Description: Humidified warm carbon dioxide gas insufflation during laparosopic procedure
Study: NCT03121417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg given IV
Study: NCT01171950

Intervention type: DEVICE
Group type: OTHER
Intervention: CentriMag Ventricular Assist System
Description: All patients will be treated with the CentriMag device for up to 30 days.
Study: NCT02836431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1mcg Intravenous
Description: DEX 1 mcg/kg Intravenously
Study: NCT03314909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HP-HD
Description: Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
Study: NCT05237778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep
Description: Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imagery Rehearsal Therapy
Description: These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
Study: NCT03114384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creation and detection of patient-respirator asynchronies
Description: The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
Study: NCT02658773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine-Prilocaine cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Study: NCT00600899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h
Description: Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h
Description: Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)